Role of bile acids in the regulation of the metabolic pathways

doi:10.4239/wjd.v7.i13.260

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 13

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (19286)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series.

Item

Count

PDF

1434

WORD

500

HTML

10207

Figures (1-5)

784

Sum=12925

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

610

Download

1545

Sum=2155

Publishing Process of This Article

Item

Count

Browse

1442

Download

2755

Sum=4197

Jul 10, 2016 (publication date) through Mar 14, 2026

Times Cited of This Article

Times Cited (71)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Diabetes. Jul 10, 2016; 7(13): 260-270
Published online Jul 10, 2016. doi: 10.4239/wjd.v7.i13.260

Role of bile acids in the regulation of the metabolic pathways

Hiroki Taoka, Yoko Yokoyama, Kohkichi Morimoto, Naho Kitamura, Tatsuya Tanigaki, Yoko Takashina, Kazuo Tsubota, Mitsuhiro Watanabe

Hiroki Taoka, Tatsuya Tanigaki, Department of Environmental Information, Keio University, Fujisawa, Kanagawa 252-0882, Japan

Yoko Yokoyama, Naho Kitamura, Graduate School of Media and Governance, Keio University, Fujisawa, Kanagawa 252-0882, Japan

Kohkichi Morimoto, Division of Endocrinology, Metabolism and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo 160-8582, Japan

Yoko Takashina, Research Institute of SFC, Keio University, Fujisawa, Kanagawa 252-0882, Japan

Kazuo Tsubota, Department of Ophthalmology, Keio University School of Medicine, Shinjuku, Tokyo 160-8582, Japan

Mitsuhiro Watanabe, Graduate School of Media and Governance, Department of Environment and Information Studies, Keio University, Fujisawa, Kanagawa 252-0882, Japan

Mitsuhiro Watanabe, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo 160-8582, Japan

Author contributions: Taoka H, Watanabe M devised the study concept and design; Taoka H, Yokoyama Y, Morimoto K, Watanabe M searched the literature; Taoka H, Yokoyama Y, Morimoto K, Kitamura N, Watanabe M drafted the article; all authors revised the article for important intellectual content; Watanabe M gave final approval for the article.

Conflict-of-interest statement: No potential conflicts of interest. No financial support.

Correspondence to: Mitsuhiro Watanabe, PhD, Professor of Graduate School of Media and Governance, Professor of Faculty of Environment and Information Studies, Graduate School of Media and Governance, Department of Environment and Information Studies, Keio University, tau42, 5322 Endo, Fujisawa, Kanagawa 252-0882, Japan. wmitsu@sfc.keio.ac.jp

Telephone: +81-466-493516 Fax: +81-466-493516

Received: October 1, 2015
Peer-review started: October 9, 2015
First decision: November 6, 2015
Revised: November 24, 2015
Accepted: May 17, 2016
Article in press: May 27, 2016
Published online: July 10, 2016
Processing time: 278 Days and 19 Hours

Core Tip

Core tip: Bile acids (BAs) are important molecules that participate in various metabolic pathways. BA signaling mechanisms are attractive therapeutic targets of the metabolic syndrome. In this review, we show the mechanisms of controlling glucose, lipid and energy metabolism via BA signaling. Furthermore, the authors also describe how those basic scientific studies have been applied to the clinical setting. Particularly, bile acid binding resin (BABR) originally used to treat hypercholesterolemia also stimulates incretin secretion and improves glucose metabolism. In addition to BABR, the clinical application of farnesoid X receptor and TGR5/M-BAR agonists are ongoing for the treatment of metabolic syndrome. The effects of bariatric surgery on glycemic control are also associated with BA metabolism.